Trials / Completed
CompletedNCT00254696
Study Evaluating Antibiotic Utilization Measures and Control of Extended-Spectrum-Lactamases (ESBLs)
Association of Antibiotic Utilization Measures and Control of Extended-spectrum-lactamases (ESBLs)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 710 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
* To determine the value of using piperacillin/tazobactam in reducing the cases of ESBL producing E. coli or K. pneumoniae colonization and infection. * To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, both pre and post intervention in the selected medical centers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Extended-Spectrum-Lactamases (ESBLs) |
Timeline
- Start date
- 2004-06-01
- Primary completion
- 2005-03-01
- Completion
- 2005-03-01
- First posted
- 2005-11-16
- Last updated
- 2011-04-15
Source: ClinicalTrials.gov record NCT00254696. Inclusion in this directory is not an endorsement.